-+ 0.00%
-+ 0.00%
-+ 0.00%

Galectin Therapeutics Q3 2026 Net Loss Applicable to Common Stockholders Narrows 56% to $3.6 Million Versus Quarter Ended June 30, 2025

PUBT·11/16/2026 12:56:55
Listen to the news
Galectin Therapeutics Q3 2026 Net Loss Applicable to Common Stockholders Narrows 56% to $3.6 Million Versus Quarter Ended June 30, 2025
  • Galectin Therapeutics’ Q3 2026 net loss applicable to common stockholders narrowed 56% to $3.6 million versus the quarter ended June 30, 2025.
  • Research and development expenses fell 38% year over year to $1.6 million, primarily due to timing of NAVIGATE clinical trial expenditures.
  • A July 31, 2026, debt-to-equity conversion eliminated approximately $105.8 million in principal and accrued interest under five credit facilities.
  • Cash totaled $11.7 million at September 30, 2026; management expects sufficient funding for planned operations through June 2027.
  • The registrational Phase 3 belapectin protocol was submitted to FDA in Q3 2026 following alignment on key trial-design elements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-043989), on November 16, 2026, and is solely responsible for the information contained therein.